|
|
Article: Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome by Forest Laboratories, Inc. and Cypress Bioscience, Inc.
- Article from:
- M2 Presswire
- Article date:
- May 23, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-23 May 2007-Making The Watchlist: Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome by Forest Laboratories, Inc. and Cypress Bioscience, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:23052007
Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Activity on the NYSE market has brought this company to the attention of our research team. Forest Laboratories, Inc. (NYSE: FRX), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively ...